Collection description
This collection contains guidelines, forms and documents related to accessing olipudase alfa (Xenpozyme®) under the Life Saving Drugs Program. Click to view the Xenpozyme® product information on the Therapeutic Goods Administration website.
Guidelines
Life Saving Drugs Program – Acid sphingomyelinase deficiency (ASMD) types A/B and B – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for acid sphingomyelinase deficiency (ASMD) types A/B and B under the Life Saving Drugs Program.
Forms
Life Saving Drugs Program – Acid sphingomyelinase deficiency (ASMD) types A/B and B – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for ASMD types A/B and B for the first time, or after a break.
Life Saving Drugs Program – Acid sphingomyelinase deficiency (ASMD) types A/B and B – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for ASMD types A/B and B.
Life Saving Drugs Program – Acid sphingomyelinase deficiency (ASMD) types A/B and B – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Publication date:
Publication type:
Collection